What those doctors would have also said is that; a) Pluvicto has been a very successful therapy, even with those side effects, b) Despite those side effects, they would recommend it to their future patients, c) The uptake is so high that there isn't enough drug to go round.
Remember: Pluvicto is slowly moving to early line treatment! That says something about efficacy and safety. It's a risk benefit analysis.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)